Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2016, Article ID 1316326, 4 pages
http://dx.doi.org/10.1155/2016/1316326
Research Article

Clinical Outcome of a Novel Anti-CD6 Biologic Itolizumab in Patients of Psoriasis with Comorbid Conditions

Vibrance Skin Clinic, 412 Pearls Best Height II, Behind Max Hospital, Netaji Subhash Place, Pitampura, Delhi 110034, India

Received 21 January 2016; Revised 14 April 2016; Accepted 28 July 2016

Academic Editor: Elizabeth H. Kemp

Copyright © 2016 Vinay Singh. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. S. Winterfield, A. Menter, K. Gordon, and A. Gottlieb, “Psoriasis treatment: current and emerging directed therapies,” Annals of the Rheumatic Diseases, vol. 64, no. 2, pp. ii87–ii90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. National Psoriasis Foundation, https://www.psoriasis.org/about-psoriasis/types/plaque.
  3. S. J. Rich and C. E. Bello-Quintero, “Advancements in the treatment of psoriasis: role of biologic agents,” Journal of Managed Care Pharmacy, vol. 10, no. 4, pp. 318–325, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. S. V. Rakhesh, M. D'Souza, and A. Sahai, “Quality of life in psoriasis: a study from south India,” Indian Journal of Dermatology, Venereology and Leprology, vol. 74, no. 6, pp. 600–606, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. N. Onumah and L. H. Kircik, “Psoriasis and its comorbidities,” Journal of Drugs in Dermatology, vol. 11, no. 5, pp. s5–s10, 2012. View at Google Scholar · View at Scopus
  6. S. J. Aurangabadkar, “Comorbidities in psoriasis,” Indian Journal of Dermatology, Venereology and Leprology, vol. 79, supplement 1, pp. S10–S17, 2013. View at Publisher · View at Google Scholar · View at Scopus
  7. A. B. Gottlieb, C. Chao, and F. Dann, “Psoriasis comorbidities,” Journal of Dermatological Treatment, vol. 19, no. 1, pp. 5–21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. K. Sivamani, G. Correa, Y. Ono, M. P. Bowen, S. P. Raychaudhuri, and E. Maverakis, “Biological therapy of psoriasis,” Indian Journal of Dermatology, vol. 55, no. 2, pp. 161–170, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. R. Menon and B. G. David, “Itolizumab—a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis,” Clinical, Cosmetic and Investigational Dermatology, vol. 8, pp. 215–222, 2015. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Kilic and S. Cakmak, “Psoriasis and comorbidities,” EMJ Dermatology, vol. 1, pp. 78–85, 2013. View at Google Scholar
  11. D. S. Krupashankar, S. Dogra, M. Kura et al., “Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study,” Journal of the American Academy of Dermatology, vol. 71, no. 3, pp. 484–492, 2014. View at Publisher · View at Google Scholar · View at Scopus